CHRS - コヒ―ラス・バイオサイエンシズ （Coherus BioSciences Inc.） コヒ―ラス・バイオサイエンシズCHRSのチャート
CHRSの企業情報
| symbol | CHRS |
|---|---|
| 会社名 | Coherus BioSciences Inc （コヒ―ラス・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 コヒラス・バイオ サイエンシズ（Coherus BioSciences Inc.）は後期臨床生物製剤のプラットフォーム企業である。同社はバイオシミラー治療薬の開発・商業化を中心とする。同社の事業は腫瘍バイオシミラー候補ペグフィルグラスチム（Neulasta）およびベバシズマブ（Avastin）を含む治療フランチャイズ、免疫学（抗TNF）バイオシミラー候補エタネルセプト（エンブレル）およびアダリムマブ（フミラ）、眼科用バイオシミラーの候補であるラニビズマブ（Lucentis）、多発性硬化症小分子治療候補CHS-131を含む。同社の製品候補パイプラインにはCHS-1701、CHS-5217、CHS-0214、CHS-1420およびCHS-3351が含まれる。CHS-1701は顆粒球コロニー刺激因子（G-CSF）製品候補である。ベバシズマブは血管内皮増殖因子A（VEGF-A）を阻害することにより血管新生を遮断する組換えヒト化モノクローナル抗体である。エタネルセプト（Enbrel）はCHS-0214のリファレンス製品である。 コヒ―ラス・バイオサイエンシズは、米国の新興バイオ医薬品会社。バイオシミラ―(後発生物製剤)治療薬の開発に従事。バイオシミラ―は、多様な疾患の治療に向け、既存のブランド生物製剤の代わりに使用でき、安価のため患者による利用拡大の可能性を備えている。本社は、カリフォルニア州レッドウッドシティ―。 Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings to the health care system. |
| 本社所在地 | 333 Twin Dolphin Drive Suite 600 Redwood City CA 94065 USA |
| 代表者氏名 | Dennis M. Lanfear Dennis M. Lanfear |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-649-3530 |
| 設立年月日 | 40422 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 122人 |
| url | www.coherus.com |
| nasdaq_url | https://www.nasdaq.com/symbol/chrs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -186.36300 |
| 終値（lastsale） | 14.14 |
| 時価総額（marketcap） | 958986493.78 |
| 時価総額 | 時価総額（百万ドル） 927.78890 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 870.30390 |
| 当期純利益 | 当期純利益（百万ドル） -195.99100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Coherus Biosciences Inc revenues decreased from $1.6M to $0K. Net loss decreased 32% to $87.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 44% to $42.7M (expense) General and administrative decrease of 23% to $25.3M (expense). |
CHRSのテクニカル分析
CHRSのニュース
Coherus gains after issuing long-term guidance 2022/03/29 16:21:47 Seeking Alpha
Coherus BioSciences <>, a biotech focused on biosimilars and immuno-oncology products, is trading higher on Tuesday after indicating its long-term prospects with plans to launch…
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting 2022/03/15 16:06:22 Benzinga
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS ) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). As of October 31, 2021, at the final analysis, a significant improvement in … Full story available on Benzinga.com
Coherus Biosciences appoints chief medical officer 2022/03/15 13:50:21 Seeking Alpha
Coherus BioSciences (CHRS) appointed Rosh Dias as chief medical officer ((CMO)).Dias joins Coherus most recently from Spruce Biosciences, where he was the CMO
Coherus NSCLC treatment toripalimab meets primary endpoint in late-stage trial 2022/03/15 13:13:02 Seeking Alpha
Coherus BioSciences (CHRS) and partner Shanghai Junshi BioSciences said that their non-small cell lung cancer therapy toripalimab led to an improvement in progression-free survival.
Coherus esophageal cancer candidate toripalimab succeeds in late-stage trial 2022/03/04 13:41:29 Seeking Alpha
Coherus BioSciences (CHRS) and Shanghai Junshi Biosciences (SHJBF) esophageal cancer candidate toripalimab met co-primary endpoints in a phase 3 trial.
Coherus BioSciences Inc. (NASDAQ:CHRS) Is 10.23% Above Its 52-Week Low, But How Long Will It Remain So? 2022/02/26 16:30:00 Marketing Sentinel
In last trading session, Coherus BioSciences Inc. (NASDAQ:CHRS) saw 0.65 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $11.73 trading at $0.27 or 2.36% at ring of the bell on the day assigns it a market valuation of $939.46M. That closing price of CHRS’s stock is … Coherus BioSciences Inc. (NASDAQ:CHRS) Is 10.23% Above Its 52-Week Low, But How Long Will It Remain So? Read More »
Coherus BioSciences'' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices 2022/02/18 10:51:49 Benzinga
Coherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on Benzinga.com
Coherus BioSciences (CHRS) Q4 2021 Earnings Call Transcript 2022/02/18 05:00:28 The Motley Fool
CHRS earnings call for the period ending December 31, 2021.
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call Transcript 2022/02/18 04:10:41 Seeking Alpha
Global Adalimumab Market Will Reach $ 28,508.07 Million by 2027||Players-CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila 2021/07/28 08:26:43 OpenPR
Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the scope of particular product with respect to the driving factors and restraints
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th 2021/07/26 20:31:00 Intrado Digital Media
REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus management team will host a conference call and webcast to discuss financial results and provide a general business update.
Adalimumab Biosimilar Sales Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:AET BioTech, Amgen, Boehringer Ingelheim, Coherus Biosciences, Fujifilm Kyowa Kirin 2021/07/25 01:10:13 Jumbo News
This report studies the Adalimumab Biosimilar Sales Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Adalimumab Biosimilar Sales market segmented by company, []
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs 2021/07/23 11:45:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) (announced a collaboration with Biovac to manufacture COVID-19 shots in South Africa) Bristol-Myers Squibb Company (NYSE: BMY ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Century Therapeutics, Inc. (NASDAQ: IPSC ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced positive data for pipeline asset in periodontal disease) Eli Lilly and Company (NYSE: LLY ) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) (reacted to its second-quarter results) Novo Nordisk A/S (NYSE: NVO ) PLx Pharma Inc. (NASDAQ: PLXP ) ResMed Inc. (NYSE: RMD ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) 23andMe Holding Co.
Behcet Disease Treatment Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:AbbVie Inc, Celgene Corp, Coherus BioSciences Inc, Novartis AG, R Pharm, Cell Medica Lt 2021/07/23 08:41:32 Jumbo News
This report studies the Behcet Disease Treatment Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Behcet Disease Treatment market segmented by company, []